A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire
- 01 Feb 2019 Status changed from recruiting to discontinued.
- 04 Jun 2018 Planned number of patients changed from 80 to 145.
- 07 Dec 2017 Status changed from not yet recruiting to recruiting.